I know things are not moving as quickly as we would like, and it's hard to have faith in management after what the last bunch did -- or didn't do, but the new management does seem to be putting this company in a good position for the future. As with the rest of the economy, turning it around can't be done in an instant. Here's some more evidence that those who hang in there for a while longer may see a nice reward.

The following is from an interview with NVLX's CEO conducted by The Wall Street Transcript, 1 June 2009:

"TWST: What are your priorities for Nuvilex? What will make the next 12 to 24 months successful for the company?

"Mr. Schmieg: In a single word, performance. We need to instill a new level of confidence in our investors through performance - setting and achieving our goals. Our initial performance milestone will be in topside revenue growth, which we have given guidance of between $3 million and $5 million for the current fiscal year that runs from May 1, 2009 through April 30, 2010. In the near term, we will be launching our Last Shot Hangover Remedy, a safe and novel blend of essential minerals and nutrients developed to help the body metabolize the sugar in alcohol, thereby preventing or minimizing a hangover. The preventative hangover remedy is packaged in a two-ounce tube and it is meant to be taken in one shot, followed by 16 ounces of water, before going to sleep. Following a successful spring break initiative to market Last Shot along with our InfinitInk, we have seen positive reactions among the key 18 to 25 year-old demographic group. We believe that the product has the potential to make significant revenue contributions.

"TWST: Would you give us some insight into your technology platform as well as the lead products that you have under development?

"Mr. Schmieg: There are various technology platforms. They include a technology we call P2E, which is an encapsulation technology for developing safe tattoo inks and can also be used for drug delivery. The second is Cinnergen. Cinnergen is our supplement formula that is engineered to help pre-diabetics and diabetics manage their metabolism. Cinnergen has now become a family of products that includes Cinnergen itself; Cinnechol, a supplement to support good cardiovascular health, and two new products. The first is our Last Shot Hangover Remedy, which is a product taken at the end of a night of imbibing and it will eliminate or nearly eliminate all of your hangover symptoms the next morning. The other is Prevorex, an appetite aid to help those who are either on diets or trying to control their calorie intake. Our third technology is Citroxin, which starts as an eco-friendly cleaner that is highly effective as a germicide and antiviral surface cleaner. Citroxin is also being developed as a nematicide and a homeopathic medicine.

"The Wall Street Transcript is a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This 107 page special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online ."

-------------end of transcript-----------------------

It seems to be that if this hangover remedy works, it should have a real good customer base in fairly short order if it's marketed right.